多西他赛与顺铂联合治疗非小细胞肺癌的效果及对患者生存时间的影响  

Efficacy of docetaxel combined with cisplatin in the treatment of non-small cell lung cancer and its influence on survival time of patients

作　　者：张华[1] 贾志阳[1] 高露露 Zhang Hua;Jia Zhiyang;Gao Lulu(Department of Imaging and Nuclear Medicine,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Gastroenterology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院影像与核医学科,450052 [2]郑州大学第一附属医院胃肠外科,450052

出　　处：《中国实用医刊》2020年第7期98-101,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨多西他赛联合顺铂治疗非小细胞肺癌(NSCLC)的疗效及对患者生存时间的影响。方法选取郑州大学第一附属医院2017年8月至2018年8月收治的晚期NSCLC患者94例,按照随机数字表法分为对照组与观察组,每组47例。对照组采取多西他赛治疗,观察组采用多西他赛与顺铂联合治疗。比较两组临床疗效、生存时间、肿瘤标志物、生活质量及不良反应发生率。结果观察组疾病总缓解率为34.04%(16/47),高于对照组的21.28%(10/47);观察组疾病总控制率为78.72%(37/47),高于对照组的63.83%(30/47),但组间比较差异未见统计学意义(P>0.05)。观察组患者中位生存期、无进展生存期长于对照组(P<0.05);治疗后,观察组血清癌胚抗原、胸苷激酶-1水平均低于对照组(P<0.05);两组患者不良反应发生情况比较差异未见统计学意义(P>0.05);治疗后,观察组生活质量评分高于对照组(P<0.05)。结论多西他赛与顺铂联合治疗NSCLC患者疗效较好,可使患者肿瘤标志物水平下降,生存时间延长,生活质量提升,且患者能较好耐受。Objective To investigate the effects of docetaxel combined with cisplatin on survival time of non-small cell lung cancer(NSCLC),and its influence on patient’s survival time.Methods Ninety-four patients with advanced NSCLC treated in the First Affiliated Hospital of Zhengzhou University from August 2017 to August 2018 were enrolled and divided into control group and observation group by random number table method,with 47 cases in each group.Patients in the control group received the docetaxel;while observation group received the cisplatin and docetaxel.The clinical efficacy,survival time,levels of serum tumor markers,quality of life and adverse reactions were compared between the two groups.Results The overall disease remission rate of the observation group was 34.04%(16/47),higher than the 21.28%(10/47)of the control group;while the overall disease control rate in the observation group was 78.72%(37/47),higher than the 63.83%(30/47)in the control group,and the difference was not significant(P>0.05).The median survival and progression-free survival of the observation group were significantly longer than those of the control group(P<0.05).The levels of carcinoembryonic antigen and thymidine kinase-1 in the observation group were lower than those in the control group after treatment(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The quality of life score in the observation group was higher than that in the control group(P<0.05).Conclusions Docetaxel combined with cisplatin has a good therapeutic effect on NSCLC patients,which can significantly reduce the levels of serum tumor markers,prolong survival time and improve quality of life,to which the patients have a good tolerance.

关 键 词：非小细胞肺癌 多西他赛 生存时间 顺铂 

分 类 号：R734[医药卫生—肿瘤]